Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Best Practice & Research. Clinical Haematology|July 13, 2010
Is MRD eradication a desirable goal in CLL?Carol Moreno, Matthias Ritgen, Andy Rawstron
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Flow cytometric MRD detection in selected mature B-cell malignanciesSebastian Böttcher, Matthias Ritgen, Michael Kneba
Hematology/Oncology Clinics of North America|April 9, 2013
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?Sebastian Böttcher, Michael Hallek, Matthias Ritgen, et al.
Acta Haematologica|June 5, 2004
Significance of minimal residual disease in lymphoid malignanciesMonika Brüggemann, Christiane Pott, Matthias Ritgen, et al.
Journal of Immunological Methods|September 27, 2005
Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphismSebastian Böttcher, Matthias Ritgen, Monika Brüggemann, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 18, 2024
MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCRChristiane Pott, Monika Brüggemann, Matthias Ritgen, et al.
Rheumatology International|May 5, 2006
C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosusFrank Moosig, Erika Fähndrich, Anja Knorr-Spahr, et al.
European Journal of Haematology|March 22, 2005
Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual diseaseChristiane Pott, Carsten Schrader, Monika Brüggemann, et al.
Pageof 8